1. Home
  2. RIGL vs GBAB Comparison

RIGL vs GBAB Comparison

Compare RIGL & GBAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • GBAB
  • Stock Information
  • Founded
  • RIGL 1996
  • GBAB 2010
  • Country
  • RIGL United States
  • GBAB United States
  • Employees
  • RIGL N/A
  • GBAB N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • GBAB Investment Managers
  • Sector
  • RIGL Health Care
  • GBAB Finance
  • Exchange
  • RIGL Nasdaq
  • GBAB Nasdaq
  • Market Cap
  • RIGL 335.5M
  • GBAB 398.8M
  • IPO Year
  • RIGL 2000
  • GBAB N/A
  • Fundamental
  • Price
  • RIGL $20.97
  • GBAB $14.80
  • Analyst Decision
  • RIGL Buy
  • GBAB
  • Analyst Count
  • RIGL 5
  • GBAB 0
  • Target Price
  • RIGL $36.40
  • GBAB N/A
  • AVG Volume (30 Days)
  • RIGL 217.1K
  • GBAB 69.4K
  • Earning Date
  • RIGL 08-05-2025
  • GBAB 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • GBAB 9.18%
  • EPS Growth
  • RIGL N/A
  • GBAB N/A
  • EPS
  • RIGL 2.08
  • GBAB N/A
  • Revenue
  • RIGL $203,077,000.00
  • GBAB N/A
  • Revenue This Year
  • RIGL $14.41
  • GBAB N/A
  • Revenue Next Year
  • RIGL $15.97
  • GBAB N/A
  • P/E Ratio
  • RIGL $10.14
  • GBAB N/A
  • Revenue Growth
  • RIGL 70.16
  • GBAB N/A
  • 52 Week Low
  • RIGL $7.48
  • GBAB $14.22
  • 52 Week High
  • RIGL $29.82
  • GBAB $17.44
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 61.71
  • GBAB 42.76
  • Support Level
  • RIGL $18.63
  • GBAB $14.72
  • Resistance Level
  • RIGL $20.99
  • GBAB $14.99
  • Average True Range (ATR)
  • RIGL 1.07
  • GBAB 0.17
  • MACD
  • RIGL 0.11
  • GBAB 0.01
  • Stochastic Oscillator
  • RIGL 82.81
  • GBAB 51.11

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About GBAB Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust of Beneficial Interest

Guggenheim Taxable Municipal Managed Duration Trust is a diversified closed-end management investment company. Its investment objective is to provide current income with a secondary objective of long-term capital appreciation. Its products include Mutual funds, Unit investment trusts, Closed-end funds, Rydex funds, Credit income fund and others.

Share on Social Networks: